Quantifying and Describing the Natural History and Costs of Alzheimer’s Disease and Effects of Hypothetical Interventions

Manuscript Number: 

19-1055R2

Author(s): 
Christopher M. Black, Maria Eriksdotter, Ron Handels, Gunilla Johansson, Rezaul K. Khandker, Stina Salomonsson, Anders Wimo, Bengt Winblad

Disclosures

Christopher M. Black

  • Equity:
    Stock owner of Merck & Co., Inc.
    Sponsors:
    Employee of Merck & Co., Inc.

Maria Eriksdotter

  • Grants
    • Agency: 
      Merck for this study
      Dates: 
      20171201-20181231

Ron Handels

  • Consulting Fees:
    Outside this project: paid advisory boards (Eisai, 2019; Roche, 2017; Piramal, 2016; Nutricia 2013).
    Grants
    • Agency: 
      outside this study: public and private-public grants from international frameworks (H2020, JPND, IMI), national frameworks (ZonMw Netherlands, Dutch Flutemetamol study, Alzheimer Research UK, Swedisch SNAC), and patient organizations. d
      Dates: 
      2012-2020

Gunilla Johansson

  • Nothing to Disclose

Rezaul K. Khandker

  • Equity:
    I am a stockholder of Merck & Co., Inc.
    Sponsors:
    I am an employee of Merck & Co., Inc.

Stina Salomonsson

  • Equity:
    Hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA.
    Sponsors:
    Outcome Research Executive Director at MSD

Anders Wimo

  • Consulting Fees:
    Biogen: Advisory board
    Grants
    • Agency: 
      Merck
      Dates: 
      2016-2019

Bengt Winblad

  • Consulting Fees:
    SAB meetings Alzinova, Axon and Resverlogix.
    Grants
    • Agency: 
      Merck Sharp & Dhome (MSD)
      Dates: 
      Supported this study